S. Peters, R. J. R. Jaeger, P. Spiteller
HPLCNP: Rt = 11.0 min. H NMR (600 MHz, CDCl3, 298 K): δ =
FULL PAPER
6.12 (s, 1 H, 10-H), 6.53 (d, J = 11.8 Hz, 1 H, 5-H), 6.83 (d, J =
1
11.8 Hz, 1 H, 4-H), 6.98 (d, J = 8.8 Hz, 1 H, 9-H), 7.18 (d, J = 0.89 (t, J = 6.6 Hz, 3 H, 18Ј-H), 1.29–1.30 (m, 10 H, 4Ј-H to 6Ј-H,
8.8 Hz, 1 H, 8-H), 7.26 (s, 1 H, 6-H) ppm. HRMS (APCI): calcd.
for C28H4035ClO3 459.2666, found 459.2660 [M + H]+. GC-MS: Ri
= 3609; m/z (%) = 460 (1) [M(37Cl)]+, 458 (3) [M(35Cl)]+, 224 (2)
16Ј-H, 17Ј-H), 1.33–1.37 (m, 4 H, 7Ј-H, 15Ј-H), 1.63 (tt, J = 7.4,
7.4 Hz, 2 H, 3Ј-H), 2.03–2.04 (m, 4 H, 8Ј-H, 14Ј-H), 2.34 (t, J =
7.4 Hz, 2 H, 2Ј-H), 2.77 (dd, J = 7.1, 7.1 Hz, 2 H, 11Ј-H), 4.55 (s,
[ M ( 3 7 C l ) – O = C = C H ( C 1 4 H 2 7 ) ] + , 2 2 2 ( 6 ) [ M ( 3 5 C l ) – 2 H, 2-H), 5.05 (s, 2 H, 11-H), 5.30–5.35 (m, 2 H, 10Ј-H, 12Ј-H),
O=C=CH(C14H27)]+, 207 (38) [M(37Cl) – O2C(CH2)7CHCH-
(CH2)5CH3]+, 205 (100) [M(35Cl) – O2C(CH2)7CHCH(CH2)5-
CH3]+, 171 (14), 170 (22), 141 (12), 131 (4), 128 (4), 115 (6), 69 (7),
55 (9), 43 (6), 41 (7).
5.35–5.40 (m, 2 H, 9Ј-H, 13Ј-H), 6.12 (s, 1 H, 10-H), 6.53 (d, J =
11.8 Hz, 1 H, 5-H), 6.83 (d, J = 11.8 Hz, 1 H, 4-H), 6.98 (d, J =
8.4 Hz, 1 H, 9-H), 7.18 (d, J = 8.4 Hz, 1 H, 8-H), 7.26 (s, 1 H, 6-
H) ppm. 13C NMR (151 MHz, CDCl3, 298 K): δ = 14.1 (C-18Ј),
22.6 (C-17Ј), 24.9 (C-3Ј), 25.6 (C-11Ј), 27.2 (C-8Ј and C-14Ј), 29.1–
29.7, (C-4Ј to C-7Ј and C-15Ј), 31.5 (C-16Ј), 34.3 (C-2Ј), 65.4 (C-
11), 72.6 (C-2), 119.4 (C-10), 120.3 (C-9), 124.2 (C-4), 127.0 (C-7),
127.9 (C-10Ј or C-12Ј), 128.0 (C-12Ј or C-10Ј), 129.5 (C-8), 130.0
(C-9Ј or C-13Ј), 130.2 (C-13Ј or C-9Ј), 130.8 (C-5a), 130.9 (C-5),
133.4 (C-6), 136.3 (C-3), 159.2 (C-9a), 173.7 (C-1Ј) ppm. GC-MS:
Ri = 3834; m/z (%) = 486 (0.3) [M(37Cl)]+, 484 (1) [M(35Cl)]+, 279
(12), 277 (7), 224 (1) [M(37Cl) – O=C=CH(C16H29)]+, 222 (4)
[M(35Cl) – O=C=CH(C16H29)]+, 207 (43) [M(37Cl) – O2C-
(C17H31)]+, 205 (100) [M(35Cl) – O2C(C17H31)]+, 171 (18), 170 (26),
141 (14), 131 (4), 128 (4), 115 (6), 95 (6), 81 (6), 67 (7), 55 (6).
{(Z)-3-(Chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl
Palmitoleate (Z-1b): Colourless solid. HPLCRP18: Rt = 26.5 min.
1
HPLCNP: Rt = 9.8 min. H NMR (600 MHz, CDCl3, 298 K): δ =
0.88 (t, J = 7.1 Hz, 3 H, 16Ј-H), 1.24–1.33 (m, 16 H, 4Ј-H to 7Ј-H
and 12Ј-H to 15Ј-H), 1.63 (tt, J = 7.2, 7.2 Hz, 2 H, 3Ј-H), 2.33 (t,
J = 7.2 Hz, 2 H, 2Ј-H), 2.00–2.01 (m, 4 H, 8Ј-H, 11Ј-H), 4.86 (s, 2
H, 2-H), 5.04 (s, 2 H, 11-H), 5.33–5.34 (m, 2 H, 9Ј-H, 10Ј-H), 6.33–
6.34 (m, 3 H, 4-H, 5-H, 10-H), 7.01 (d, J = 8.6 Hz, 1 H, 9-H), 7.16
(dd, J = 8.6, 2.2 Hz, 1 H, 8-H), 7.18 (d, J = 2.2 Hz, 1 H, 6-H) ppm.
13C NMR (151 MHz, CDCl3, 298 K): δ = 14.1 (C-16Ј), 22.7 (C-
15Ј), 25.0 (C-3Ј), 27.2 (C-8Ј and C-11Ј) 29.1–29.8 (C-4Ј–C-7Ј and
C-12Ј–C-13Ј), 31.9 (C-14Ј) 34.3 (C-2Ј), 65.4 (C-11), 68.1 (C-2),
120.2 (C-10), 120.3 (C-9), 127.7 (C-7), 127.8 (C-4 or C-5), 128.1
(C-5 or C-4), 128.9 (C-8), 129.7 (C-9Ј or C-10Ј), 130.0 (C-10Ј or C-
9Ј), 131.0 (C-5a), 132.4 (C-6), 138.2 (C-3), 159.0 (C-9a) 173.7 (C-
1Ј) ppm. GC-MS: Ri = 3593; m/z: see E-1b.
{(Z)-3-(Chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl Li-
noleate (Z-1e): Colourless solid. Rt = 26.5 min. HPLCNP: Rt =
10.2 min. 1H NMR (600 MHz, CDCl3, 298 K): δ = 0.88 (t, J =
7.4 Hz, 3 H, 18Ј-H), 1.29–1.37 (m, 14 H, 4Ј-H to 7Ј-H and 15Ј-H
to 17Ј-H), 1.63 (tt, J = 6.4, 6.4 Hz, 2 H, 3Ј-H), 2.00–2.05 (m, 4 H,
8Ј-H, 14Ј-H), 2.34 (t, J = 6.4 Hz, 2 H, 2Ј-H), 2.77 (dd, J = 6.9,
6.9 Hz, 2 H, 11Ј-H), 4.86 (s, 2 H, 2-H), 5.05 (s, 2 H, 11-H), 5.31–
5.35 (m, 2 H, 10Ј-H, 12Ј-H), 5.34–5.38 (m, 2 H, 9Ј-H, 13Ј-H), 6.33–
6.34 (m, 3 H, 4-H, 5-H, 10-H), 7.01 (d, J = 8.5 Hz, 1 H, 9-H), 7.17
(d, J = 8.5 Hz, 1 H, 8-H), 7.21 (s, 1 H, 6-H) ppm. GC-MS: Ri =
3815; m/z: see E-1e.
{(E)-3-(Chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl
Stearate (E-1c): GC-MS: Ri = 3861; m/z (%) = 490 (14)
[M(37Cl)]+, 488 (32) [M(35Cl)]+, 279 (2), 277 (2), 224 (16) [M(37Cl) –
O=C=CH(CH2)15CH3]+, 222 (47) [M(35Cl) – O=C=CH(CH2)15
-
CH3]+, 207 (38) [M(37Cl) – O2C(CH2)15CH3]+, 205 (100) [M(35Cl) –
O2C(CH2)15CH3]+, 171 (33), 170 (46), 141 (25), 131 (10), 128 (4),
115 (10), 69 (11), 67 (10), 57 (14), 55 (14).
(2,3-Dihydro-3-methylenebenzo[b]oxepin-7-yl)methanol (2): Colour-
1
less solid. HPLCRP18: Rt = 8.9 min. H NMR (600 MHz, CDCl3,
{(Z)-3-(Chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl
Stearate (Z-1c): GC-MS: Ri = 3847; m/z: see E-1c.
298 K): δ = 4.58 (s, 2 H, 2-H), 4.64 (s, 2 H, 11-H), 5.07 (s, 1 H, 10-
Hb), 5.23 (s, 1 H, 10-Ha), 6.35 (d, J = 11.6 Hz, 1 H, 5-H), 6.47 (d,
J = 11.6 Hz, 1 H, 4-H), 6.99 (d, J = 8.2 Hz, 1 H, 9-H), 7.16 (dd, J
= 8.2, 2.0 Hz, 1 H, 8-H), 7.24 (d, J = 2.0 Hz, 1 H, 6-H) ppm.
{(E)-3-(Chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl
Oleate (E-1d): Colourless solid. HPLCRP18: Rt = 28.2 min.
1
HPLCNP: Rt = 10.6 min. H NMR (500 MHz, CDCl3, 298 K): δ =
0.88 (t, J = 6.7 Hz, 3 H, 18Ј-H), 1.27–1.29 (m, 20 H, 4Ј-H to 7Ј-H (2,3-Dihydro-3-methylenebenzo[b]oxepin-7-yl)methyl Trimethylsilyl
and 12Ј-H to 17Ј-H), 1.64 (tt, J = 7.6, 7.6 Hz, 2 H, 3Ј-H), 1.98– Ether (Trimethylsilyl Derivative of 2): GC-MS: Ri = 1864; m/z (%)
2.03 (m, 4 H, 8Ј-H, 11Ј-H), 2.34 (t, J = 7.6 Hz, 2 H, 2Ј-H), 4.55 (s, = 260 (64) [M]+, 245 (10), 215 (13), 186 (4), 185 (5), 171 (100) [M –
2 H, 2-H), 5.05 (s, 2 H, 11-H), 5.32–5.37 (m, 2 H, 9Ј-H, 10Ј-H), OSi(CH3)3]+, 141 (13), 131 (6), 128 (19), 115 (10), 75 (6), 73 (6).
6.12 (s, 1 H, 10-H), 6.53 (d, J = 11.9 Hz, 1 H, 5-H), 6.83 (d, J =
(2,3-Dihydro-3-methylenebenzo[b]oxepin-7-yl)methyl Palmitate (2a):
11.9 Hz, 1 H, 4-H), 6.98 (d, J = 8.0 Hz, 1 H, 9-H), 7.18 (dd, J =
Colourless solid. HPLCRP18: Rt = 28.2 min. HPLCNP: Rt = 8.4 min.
8.0, J = 2.4 Hz, 1 H, 8-H), 7.26 (d, J = 2.4 Hz, 1 H, 6-H) ppm.
1H NMR: see Table 1. 13C NMR: see Table 1. UV/Vis (H2O): λmax
13C NMR (126 MHz, CDCl3, 298 K): δ = 14.1 (C-18Ј), 22.7 (C-
(lg ε) = 236 (4.42), 282 (4.34) nm. GC-MS: Ri = 3353; m/z (%) =
17Ј), 25.0 (C-3Ј), 27.2 (C-8Ј and C-11Ј) 29.1–29.8 (C-4Ј–C-7Ј and
426 (11) [M]+, 188 (42) [M – O=C=CH(CH2)13CH3]+, 172 (78), 171
C-12Ј–C-15Ј), 31.9 (C-16Ј) 34.3 (C-2Ј), 65.4 (C-11), 72.6 (C-2),
(100) [M – O2C(CH2)14CH3]+, 159 (6), 157 (8), 141 (8), 131 (5), 128
119.4 (C-10), 120.3 (C-9), 124.2 (C-4), 127.0 (C-7), 129.4 (C-8),
(15), 115 (6), 57 (6), 55 (6), 43 (10), 41 (6).
129.7 (C-9Ј or C-10Ј), 130.0 (C-10Ј or C-9Ј), 130.8 (C-5a), 130.9 (C-
(2,3-Dihydro-3-methylenebenzo[b]oxepin-7-yl)methyl Palmitoleate
(2b): Colourless solid. HPLCRP18: Rt = 26.5 min. HPLCNP: Rt =
8.6 min. GC-MS: Ri = 3336; m/z (%) = 424 (1) [M]+, 188 (7) [M –
O=C=CHC14H27]+, 172 (83) 171 (100) [M – O2C(CH2)7-
CHCH(CH2)5CH3]+, 157 (4), 141 (4), 131 (3), 128 (11), 115 (4), 69
(4), 55 (6), 43 (4), 41 (5).
5), 133.4 (C-6), 136.4 (C-3), 159.2 (C-9a) 173.6 (C-1Ј) ppm. HRMS
(APCI): calcd. for C30H4435ClO3 487.2979, found 487.2977 [M +
H]+. GC-MS: Ri = 3835; m/z (%) = 488 (0.3) [M(37Cl)]+, 486 (1)
[M(35Cl)]+, 279 (6), 277 (4), 224 (1) [M(37Cl) – O=C=CH-
(C16H31)]+, 222 (4) [M(35Cl) – O=C=CH(C16H31)]+, 207 (38)
[M(37Cl) – O2C(C17H33)]+, 205 (100) [M(35Cl) – O2C(C17H33)]+,
171 (12), 170 (20), 141 (10), 131 (3), 128 (3), 115 (4), 95 (3), 81 (4),
69 (5), 67 (10), 55 (7), 43 (4), 41 (6).
(2,3-Dihydro-3-methylenebenzo[b]oxepin-7-yl)methyl Stearate (2c):
GC-MS: Ri = 3545; m/z (%) = 454 (6) [M]+, 188 (26) [M –
O2C(CH2)16CH3]+, 172 (88), 171 (100) [M – O2C(CH2)16CH3]+, 157
(8), 131 (6), 128 (14), 115 (6), 57 (86), 55 (6), 43 (12).
{(Z)-3-(Chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl
Oleate (Z-1d): GC-MS: Ri = 3819; m/z: see E-1d.
{(E)-3-(Chloromethylene)-2,3-dihydrobenzo[b]oxepin-7-yl}methyl Li-
noleate (E-1e): Colourless solid. HPLCRP18: Rt = 26.5 min.
(2,3-Dihydro-3-methylenebenzo[b]oxepin-7-yl)methyl Oleate (2d):
GC-MS: Ri = 3543; m/z (%) = 452 (1) [M]+, 281 (3), 277 (6), 188
1192
www.eurjoc.org
© 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2008, 1187–1194